Afirma XA results may offer important prognostic insights; for example, nodules with a non-RAS and non- BRAF molecular profile have lower rates of lymph node metastasis and extrathyroidal extension (74). The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.